Movetis Seeking €112.5M: Is End to Europe's IPO Drought Near?
BioWorld International Correspondent
Movetis NV is testing the mettle of European life sciences investors with the sector's first sizeable initial public offering since the first quarter of 2008.
With a European product launch imminent, the company offers a far less risky proposition than most, however.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter